The COVID-19 Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation on Tuesday accepted the phase-3 trial data of Bharat Biotech's COVID-19 vaccine Covaxin.
As per data submitted by the Bharat Biotech, it said that Covaxin has shown 77.8 percent efficacy in the trial conducted on 25,800 subjects, sources told CNBC-TV18.
The data came a day before Bharat Biotech is expected to attend a "pre-submission" meeting on July 23 with the World Health Organisation (WHO), which will take the vaccine-maker closer to a WHO Emergency Use Listing (EUL).
Covaxin is one of the three vaccines approved by the DGCI for emergency use and is being deployed in India's COVID-19 vaccination programme.
Here is a look at the efficacy rate of other vaccines:
Another indigenously developed vaccine has an efficacy rate of 80 percent if the gap between the two doses of the vaccine is 12-16 weeks. The Oxford-AstraZeneca vaccine is being manufactured by the Serum Institute of India.
Sputnik V: According to late-stage trial results published in The Lancet, Russia's Sputnik V coronavirus vaccine offers around 92 percent protection. It is the third vaccine to be approved for emergency use in India.
Moderna: It is 94.1 percent effective at preventing symptomatic infection in people. The two doses of Moderna mRNA-1273 vaccine are being administered in the gap of four-six weeks.
Pfizer-BioNTech: The vaccine offers 95 percent efficacy in preventing COVID-19 in those without previous infection. The vaccine was 100 percent effective against severe disease, and 95.3 percent effective against severe COVID-19. The Phase 3 study data was collected from more than 12,000 vaccinated participants.
Johnson & Johnson: In the US, it offers 72 percent overall efficiency and 86 percent efficiency against severe diseases.